Repeated bone targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical Rhenium-188 HEDP

P967

  • Schmidt-Wolf, I.
  • Palmedo, H.
  • Manka-Waluch, A.
  • Albers, P.
  • Reinhardt, M.
  • Ezziddin, S.
  • Joe, A.
  • Roedel, R.
  • Fimmers, R.
  • Knapp, F.
  • Guhlke, S.
  • Biersack, H.

  • Bonn, Kassel, D

Onkologie 26:p 200, October 2003.
Copyright © 2003 S. Karger AG, Basel